Drug profile
The FDA adverse-event record for Senvelgo Velagliflozin Oral Solution
164 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Senvelgo Velagliflozin Oral Solution. See the species affected, top reactions, and outcomes below.
- 164
- adverse-event reports
- 14.6%
- death-coded share
- Cat
- most-reported species
- 53
- Ketosis - top reaction
Active Ingredients
Administration Routes
Species Affected
Most Affected Breeds
Most Reported Reactions
Outcome Breakdown
Senvelgo Velagliflozin Oral Solution Adverse Event Insights
164 reports name Senvelgo Velagliflozin Oral Solution; 24 recorded a death outcome (14.6% of reported events, not a population-level mortality rate). Active ingredient: Senvelgo Velagliflozin Oral Solution. Administration routes: Oral, Unknown, Subcutaneous.
By species: Cat (164 reports). By breed: Domestic Shorthair (124), Domestic Longhair (14), Domestic Mediumhair (7).
Leading clinical signs: Ketosis (53), Lack of efficacy - NOS (39), Weight loss (38), Vomiting (31). Outcome, 164 coded reports: Outcome Unknown leads at 61.0%.
Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.